| Deaconess Vna 610 E Walnut St, Evansville, IN, 47734 | |
| (812) 425-3561 |
News Archive
In this post in the Guardian's "The Observer," Mark Honigsbaum, a research associate at the University of Zurich's Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague François Lévesque "have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the" sweet wormwood plant from which it is extracted.
Significant research funding in the form of a five-year, $12.1 million U19 Grant from the National Institutes of Health has been awarded to a collaboration of research teams co-led by Dartmouth's Christopher Amos, PhD, to study and improve precision of lung cancer risk and screening.
Protein expression of the tumor suppressing gene Rb2/p130 could play a vital role in ovarian cancer, according to a study by researchers at the Sbarro Institute for Cancer Research and Molecular Medicine in the Center for Biotechnology at Temple University
GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO's motion to dismiss its litigation over Final Regulations published in August 2007 (Triantafyllos Tafas and SmithKline Beecham Corporation, SmithKline Beecham PLC and Glaxo Group Limited vs. David J. Kappos and the United States Patent and Trademark Office).
› Verified 2 days ago
| Name | Deaconess Vna |
|---|---|
| Location | 610 E Walnut St, Evansville, Indiana |
| Hospice ID | 151518 |
| Category | Freestanding Hospice |
| Ownership Type | Voluntary Non-profit - Other |
| Profit Type | NON-PROFIT |
| SSA county code | 810 |
News Archive
In this post in the Guardian's "The Observer," Mark Honigsbaum, a research associate at the University of Zurich's Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague François Lévesque "have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the" sweet wormwood plant from which it is extracted.
Significant research funding in the form of a five-year, $12.1 million U19 Grant from the National Institutes of Health has been awarded to a collaboration of research teams co-led by Dartmouth's Christopher Amos, PhD, to study and improve precision of lung cancer risk and screening.
Protein expression of the tumor suppressing gene Rb2/p130 could play a vital role in ovarian cancer, according to a study by researchers at the Sbarro Institute for Cancer Research and Molecular Medicine in the Center for Biotechnology at Temple University
GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO's motion to dismiss its litigation over Final Regulations published in August 2007 (Triantafyllos Tafas and SmithKline Beecham Corporation, SmithKline Beecham PLC and Glaxo Group Limited vs. David J. Kappos and the United States Patent and Trademark Office).
› Verified 2 days ago
| NPI Number | 1821173790 |
| Organization Name | Deaconess Vna Plus, Llc |
| Address | 610 E Walnut St Evansville, Indiana, 47713 |
| Phone Number | (812)425-3561 |
News Archive
In this post in the Guardian's "The Observer," Mark Honigsbaum, a research associate at the University of Zurich's Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague François Lévesque "have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the" sweet wormwood plant from which it is extracted.
Significant research funding in the form of a five-year, $12.1 million U19 Grant from the National Institutes of Health has been awarded to a collaboration of research teams co-led by Dartmouth's Christopher Amos, PhD, to study and improve precision of lung cancer risk and screening.
Protein expression of the tumor suppressing gene Rb2/p130 could play a vital role in ovarian cancer, according to a study by researchers at the Sbarro Institute for Cancer Research and Molecular Medicine in the Center for Biotechnology at Temple University
GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO's motion to dismiss its litigation over Final Regulations published in August 2007 (Triantafyllos Tafas and SmithKline Beecham Corporation, SmithKline Beecham PLC and Glaxo Group Limited vs. David J. Kappos and the United States Patent and Trademark Office).
› Verified 2 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 99.4 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 95.5 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 99.8 | 97.3 |
| Patients who got timely treatment for shortness of breath | 99.6 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
In this post in the Guardian's "The Observer," Mark Honigsbaum, a research associate at the University of Zurich's Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague François Lévesque "have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the" sweet wormwood plant from which it is extracted.
Significant research funding in the form of a five-year, $12.1 million U19 Grant from the National Institutes of Health has been awarded to a collaboration of research teams co-led by Dartmouth's Christopher Amos, PhD, to study and improve precision of lung cancer risk and screening.
Protein expression of the tumor suppressing gene Rb2/p130 could play a vital role in ovarian cancer, according to a study by researchers at the Sbarro Institute for Cancer Research and Molecular Medicine in the Center for Biotechnology at Temple University
GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO's motion to dismiss its litigation over Final Regulations published in August 2007 (Triantafyllos Tafas and SmithKline Beecham Corporation, SmithKline Beecham PLC and Glaxo Group Limited vs. David J. Kappos and the United States Patent and Trademark Office).
› Verified 2 days ago
| Home Health Aides | 5.2 |
| Counselors | 2 |
| Licensed Practical or Vocational Nurses | 3 |
| Medical Social Workers | 4 |
| Physicians | 4 |
| Registered Nurses | 18.2 |
| Other Personnel | 44 |
| Total Employees | 80.4 |
|---|
News Archive
In this post in the Guardian's "The Observer," Mark Honigsbaum, a research associate at the University of Zurich's Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague François Lévesque "have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the" sweet wormwood plant from which it is extracted.
Significant research funding in the form of a five-year, $12.1 million U19 Grant from the National Institutes of Health has been awarded to a collaboration of research teams co-led by Dartmouth's Christopher Amos, PhD, to study and improve precision of lung cancer risk and screening.
Protein expression of the tumor suppressing gene Rb2/p130 could play a vital role in ovarian cancer, according to a study by researchers at the Sbarro Institute for Cancer Research and Molecular Medicine in the Center for Biotechnology at Temple University
GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO's motion to dismiss its litigation over Final Regulations published in August 2007 (Triantafyllos Tafas and SmithKline Beecham Corporation, SmithKline Beecham PLC and Glaxo Group Limited vs. David J. Kappos and the United States Patent and Trademark Office).
› Verified 2 days ago
| Others | 81 |
| Total Volunteers | 81 |
|---|
News Archive
In this post in the Guardian's "The Observer," Mark Honigsbaum, a research associate at the University of Zurich's Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague François Lévesque "have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the" sweet wormwood plant from which it is extracted.
Significant research funding in the form of a five-year, $12.1 million U19 Grant from the National Institutes of Health has been awarded to a collaboration of research teams co-led by Dartmouth's Christopher Amos, PhD, to study and improve precision of lung cancer risk and screening.
Protein expression of the tumor suppressing gene Rb2/p130 could play a vital role in ovarian cancer, according to a study by researchers at the Sbarro Institute for Cancer Research and Molecular Medicine in the Center for Biotechnology at Temple University
GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO's motion to dismiss its litigation over Final Regulations published in August 2007 (Triantafyllos Tafas and SmithKline Beecham Corporation, SmithKline Beecham PLC and Glaxo Group Limited vs. David J. Kappos and the United States Patent and Trademark Office).
› Verified 2 days ago
| Deaconess Vna Location: 610 E Walnut St, Evansville, Indiana, 47734 Phone: (812) 425-3561 |
| Kindred Hospice Location: 323 Metro Ave, Evansville, Indiana, 47715 Phone: (812) 425-3561 |
| Medical Services Of America Hospice Location: 3101 North Green River Road, Suite 210, Evansville, Indiana, 47715 Phone: (812) 425-3561 |
| Heritage Hospice Inc Location: 1202 W Buena Vista Rd Ste 107, Evansville, Indiana, 47710 Phone: (812) 425-3561 |